INSERM U-955, Team No. 10, Institut Mondor de Recherche Biomédicale, Université Paris Est, 94010 Créteil, Paris, France.
Curr Drug Targets. 2011 Jun;12(7):1082-93. doi: 10.2174/138945011795677764.
Cyclooxygenase-2 (Cox-2) is an inducible enzyme involved in the conversion of arachidonic acid to prostaglandin and other eicosanoids. Molecular pathology studies have revealed that Cox-2 is over-expressed in cancer and stroma cells during tumor progression, and anti-cancer chemo-radiotherapies induce expression of Cox-2 in cancer cells. Elevated tumor Cox-2 is associated with increased angiogenesis, tumor invasion and promotion of tumor cell resistance to apoptosis. Several experimental and clinical studies have established potent anti-cancer activity of NSAID (Non-steroidal anti-inflammatory drugs) and other Cox-2 inhibitors such as celecoxib. Much attention is being focused on Cox-2 inhibitors as beneficial target for cancer chemotherapy. The mode of action of Cox-2 and its inhibitors remains unclear. Further clinical application needs to be investigated for comprehending Cox-2 biological functions and establishing it as an effective target in cancer therapy.
环氧化酶-2(Cox-2)是一种诱导酶,参与花生四烯酸转化为前列腺素和其他类二十烷酸。分子病理学研究表明,Cox-2 在肿瘤进展过程中在癌细胞和基质细胞中过度表达,抗癌化疗和放疗诱导 Cox-2 在癌细胞中的表达。升高的肿瘤 Cox-2 与血管生成增加、肿瘤侵袭和促进肿瘤细胞抗凋亡有关。几项实验和临床研究已经证实了 NSAID(非甾体抗炎药)和其他 Cox-2 抑制剂(如塞来昔布)的强大抗癌活性。人们非常关注 Cox-2 抑制剂作为癌症化疗的有益靶点。Cox-2 及其抑制剂的作用模式仍不清楚。需要进一步的临床应用来研究 Cox-2 的生物学功能,并将其确立为癌症治疗的有效靶点。